FAQ

elbasvir / grazoprevir

Known as: ELBASVIR/GRAZOPREVIR, elbasvir and grazoprevir 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
01220162018

Related topics

Related topics

2 relations
elbasvirgrazoprevir

Related mentions per year

Related mentions per year

2014-2018
201020122014201620182020
elbasvir / grazoprevir
grazoprevir
elbasvir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial.
Many direct-acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT)3 infection and… (More)
Is this relevant?
2017
2017
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Direct-acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HCV) infection… (More)
Is this relevant?
2017
2017
No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole
Use of agents to suppress gastric acid secretion is common among patients with hepatitis C virus (HCV) infection. The aims of… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2017
2017
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
Direct-acting antiviral agents have not been studied exclusively in patients with inherited blood disorders and hepatitis C virus… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2017
2017
The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir…
BACKGROUND The presence of baseline NS5A resistance-associated variants (RAVs) impacted treatment response in HCV genotype 1a… (More)
Is this relevant?
2017
2017
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.
Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five… (More)
  • table 1
  • table 2
  • table 4
  • figure 1
  • table 3
Is this relevant?
2017
2017
Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
Among patients with chronic kidney disease (CKD) in the United States, HCV infection causes significant morbidity and mortality… (More)
Is this relevant?
2016
2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
BACKGROUND & AIMS Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2016
Review
2016
Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.
INTRODUCTION During the last few years, treatment of hepatitis C virus (HCV) revolutionized with the appearance of direct… (More)
Is this relevant?